Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: A Comprehensive literature review

Reviews in Medical Virology

Volumn 23, Issue 5, 2013, Pages 295-304

  Zhou, Xinying ^a   de Man, Robert A ^a   de Knegt, Robert J ^a   Metselaar, Herold J ^a   Peppelenbosch, Maikel P ^a   Pan, Qiuwei ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; GENOMIC RNA; HEPATITIS E ANTIBODY; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RIBAVIRIN; TACROLIMUS;

CHRONIC DISEASE; DISEASE COURSE; GRAFT REJECTION; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; PREVALENCE; REVIEW;

EID: 84882691614     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1751     Document Type: Review

References (74)

1. Dalton HR. Hepatitis: hepatitis E and decompensated chronic liver disease. Nature Reviews. Gastroenterology & Hepatology 2012; 9: 430-432.
2. Park SB. Hepatitis E vaccine debuts. Nature 2012; 491: 21-22.
3. Ahmad I, Holla RP, Jameel S. Molecular virology of hepatitis E virus. Virus Research 2011; 161: 47-58.
4. Mushahwar IK. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. Journal of Medical Virology 2008; 80: 646-658.
5. Purdy MA, Khudyakov YE. The molecular epidemiology of hepatitis E virus infection. Virus Research 2011; 161: 31-39.
6. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012; 379: 2477-2488.
7. Raj VS, Smits SL, Pas SD, et al. Novel hepatitis E virus in ferrets, the Netherlands. Emerging Infectious Diseases 2012; 18: 1369-1370.
8. Moal V, Zandotti C, Colson P. Emerging viral diseases in kidney transplant recipients. Reviews in Medical Virology 2013; 23: 50-69.
9. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. The New England Journal of Medicine 2008; 358: 811-817.
10. Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. Journal of Viral Hepatitis 2012; 19: 1-8.
11. Pan Q, Tilanus HW, Metselaar HJ, Janssen HL, van der Laan LJ. Virus-drug interactions-molecular insight into immunosuppression and HCV. Nature Reviews. Gastroenterology & Hepatology 2012; 9: 355-362.
12. Borgen K, Herremans T, Duizer E, et al. Non-travel related Hepatitis E virus genotype 3 infections in the Netherlands; a case series 2004-2006. BMC Infectious Diseases 2008; 8: 61.
13. Aggarwal R, Jameel S. Hepatitis E. Hepatology 2011; 54: 2218-2226.
14. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. American Journal of Medicine 1981; 70: 252-255.
15. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. The New England Journal of Medicine 2012; 367: 1237-1244.
16. De Silva S, Hassan-Ibrahim MO, Austin M, Newport M, Verma S. Hepatitis E infection is an under recognized cause of acute decompensation in patients with chronic liver disease. Digestive and Liver Disease 2012; 44: 930-934.
17. Kamar N, Legrand-Abravanel F, Izopet J, Rostaing L. Hepatitis E virus: what transplant physicians should know. American Journal of Transplantation 2012; 12: 2281-2287.
18. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. The New England Journal of Medicine 2009; 361: 1025-1027.
19. Ollier L, Tieulie N, Sanderson F, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Annals of Internal Medicine 2009; 150: 430-431.
20. Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. Journal of Gastroenterology and Hepatology 2009; 24: 1484-1493.
21. Tsang TH, Denison EK, Williams HV, Venczel LV, Ginsberg MM, Vugia DJ. Acute hepatitis E infection acquired in California. Clinical Infectious Diseases 2000; 30: 618-619.
22. Ijaz S, Arnold E, Banks M, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. Journal of Infectious Diseases 2005; 192: 1166-1172.
23. Mansuy JM, Peron JM, Abravanel F, et al. Hepatitis E in the south west of France in individuals who have never visited an endemic area. Journal of Medical Virology 2004; 74: 419-424.
24. Scotto G, Martinelli D, Giammario A, Prato R, Fazio V. Prevalence of antibodies to hepatitis E virus in immigrants: a seroepidemiological survey in the district of foggia (Apulia-southern Italy). Journal of Medical Virology 2013; 85: 261-265.
25. Buffet C, Laurent-Puig P, Chandot S, et al. A high hepatitis E virus seroprevalence among renal transplantation and haemophilia patient populations. Journal of Hepatology 1996; 24: 122-125.
26. Maylin S, Stephan R, Molina JM, et al. Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised. Journal of Clinical Virology 2012; 53: 346-349.
27. Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerging Infectious Diseases 2011; 17: 30-37.
28. Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transplantation 2010; 16: 74-82.
29. Pischke S, Stiefel P, Franz B, et al. Chronic hepatitis E in heart transplant recipients. American Journal of Transplantation 2012; 12: 3128-3133.
30. Hoerning A, Hegen B, Wingen AM, et al. Prevalence of hepatitis E virus infection in pediatric solid organ transplant recipients-a single-center experience. Pediatric Transplantation 2012; 16: 742-747.
31. Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transplantation 2009; 15: 1225-1228.
32. Halac U, Beland K, Lapierre P, et al. Chronic hepatitis E infection in children with liver transplantation. Gut 2012; 61: 597-603.
33. Rostamzadeh Khameneh Z, Sepehrvand N, Masudi S. Seroprevalence of hepatitis E among Iranian renal transplant recipients. Hepatitis Monthly 2011; 11: 646-651.
34. Smith DB, Purdy MA, Simmonds P. Genetic variability and the classification of hepatitis E virus. Journal of Virology 2013; 87: 4161-4169.
35. Baylis SA, Hanschmann KM, Blumel J, Nubling CM, Group HEVCS. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. Journal of Clinical Microbiology 2011; 49: 1234-1239.
36. Moal V, Legris T, Burtey S, et al. Infection with hepatitis E virus in kidney transplant recipients in southeastern France. Journal of Medical Virology 2013; 85: 462-471.
37. Pas SD, de Man RA, Mulders C, et al. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerging Infectious Diseases 2012; 18: 869-872.
38. Riezebos-Brilman A, Puchhammer-Stockl E, van der Weide HY, et al. Chronic hepatitis E infection in lung transplant recipients. The Journal of Heart and Lung Transplantation 2013; 32: 341-346.
39. Passos AM, Heringer TP, Medina-Pestana JO, Ferraz ML, Granato CF. First report and molecular characterization of hepatitis E virus infection in renal transplant recipients in Brazil. Journal of Medical Virology 2013; 85: 615-619.
40. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-1489.
41. Kamar N, Mansuy JM, Cointault O, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. American Journal of Transplantation 2008; 8: 1744-1748.
42. Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. The New England Journal of Medicine 2008; 358: 859-860.
43. Haagsma EB, van den Berg AP, Porte RJ, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transplantation 2008; 14: 547-553.
44. Koning L, Pas SD, de Man RA, et al. Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. The Journal of Heart and Lung Transplantation 2013; 32: 78-85.
45. van der Laan LJ, Hudson M, McPherson S, et al. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. Transplantation Proceedings 2010; 42: 4573-4577.
46. Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 2010; 89: 353-360.
47. Kamar N, Weclawiak H, Guilbeau-Frugier C, et al. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation 2012; 93: 617-623.
48. Halleux D, Kanaan N, Kabamba B, Thomas I, Hassoun Z. Hepatitis E virus: an underdiagnosed cause of chronic hepatitis in renal transplant recipients. Transplant Infectious Disease 2012; 14: 99-102.
49. Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E:a single-centre experience. Liver International 2013; 33: 722-726.
50. Pan Q, Peppelenbosch MP, Janssen HL, de Knegt RJ. Telaprevir/boceprevir era: from bench to bed and back. World Journal of Gastroenterology 2012; 18: 6183-6188.
51. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650.
52. Dalton HR, Keane FE, Bendall R, Mathew J, Ijaz S. Treatment of chronic hepatitis E in a patient with HIV infection. Annals of Internal Medicine 2011; 155: 479-480.
53. Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transplantation 2010; 16: 474-477.
54. Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clinical Infectious Diseases 2010; 50: e30-33.
55. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 2010; 139: 1612-1618.
56. Weimar W, Kramer P, Bijnen AB, Jeekel J, Rothbarth PH, Masurel N. The incidence of cytomegalo- and herpes simplex virus infections in renal allograft recipients treated with high dose recombinant leucocyte interferon: a controlled study. Scandinavian Journal of Urology and Nephrology. Supplementum 1985; 92: 37-39.
57. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431.
58. Pan Q, Tilanus HW, Janssen HL, van der Laan LJ. Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. Hepatology 2011; 53: 1400-1401; author reply 1402.
59. Lee JH, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. Journal of Hepatology 1998; 29: 29-35.
60. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-714.
61. Rotman Y, Noureddin M, Feld JJ, et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2013. DOI: 10.1136/gutjnl-2012-303852
62. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48weeks or for 24weeks versus interferon alpha2b plus placebo for 48weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
63. Gerolami R, Borentain P, Raissouni F, Motte A, Solas C, Colson P. Treatment of severe acute hepatitis E by ribavirin. Journal of Clinical Virology 2011; 52: 60-62.
64. Goyal R, Kumar A, Panda SK, Paul SB, Acharya SK. Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antiviral Therapy 2012; 17: 1091-1096.
65. de Niet A, Zaaijer HL, ten Berge I, Weegink CJ, Reesink HW, Beuers U. Chronic hepatitis E after solid organ transplantation. The Netherlands Journal of Medicine 2012; 70: 261-266.
66. Chaillon A, Sirinelli A, De Muret A, Nicand E, d'Alteroche L, Goudeau A. Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. The Journal of Heart and Lung Transplantation 2011; 30: 841-843.
67. Mallet V, Nicand E, Sultanik P, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Annals of Internal Medicine 2010; 153: 85-89.
68. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. Journal of Medical Virology 2010; 82: 799-805.
69. Ghabrah TM, Tsarev S, Yarbough PO, Emerson SU, Strickland GT, Purcell RH. Comparison of tests for antibody to hepatitis E virus. Journal of Medical Virology 1998; 55: 134-137.
70. Shukla P, Nguyen HT, Faulk K, et al. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. Journal of Virology 2012; 86: 5697-5707.
71. Purcell RH, Emerson SU. Animal models of hepatitis A and E. ILAR Journal 2001; 42: 161-177.
72. Boonstra A, van der Laan LJ, Vanwolleghem T, Janssen HL. Experimental models for hepatitis C viral infection. Hepatology 2009; 50: 1646-1655.
73. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972.
74. Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 2011; 1: 590-598.